1
`
`Grün. Exh. 1038
`PGR for U.S. Patent No. 9,931,352
`
`Grün. Exh. 1035
`PGR for U.S. Patent No. 10,052,338
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your
`submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of
`the Act, please be advised that: (1) the general authority forthe collection ofthis information is 35 U.S.C. 2(b)(2); (2)
`furnishing ofthe information solicited is voluntary; and (3) the principal purpose for which the information is used by the
`US. Patent and Trademark Office is to process and/or examine your submission related to a patent application or
`patent.
`If you do not furnish the requested information, the US Patent and Trademark Office may not be able to
`process and/or examine your submission, which may result in termination of proceedings or abandonment ofthe
`application or expiration of the patent.
`
`The information provided by you in this form will be subject to the following routine uses:
`
`1. The information on this form will be treated confidentially to the extent allowed underthe Freedom of
`Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may
`be disclosed to the Department ofJustice to determine whether disclosure ofthese records is required by the
`Freedom of Information Act.
`A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence
`to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of
`settlement negotiations.
`A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
`request involving an individual, to whom the record pertains, when the individual has requested assistance from
`the Member with respect to the subject matter ofthe record.
`A record in this system of records may be disclosed, as a routine use, to a contractor ofthe Agency having
`need forthe information in orderto perform a contract. Recipients of information shall be required to comply
`with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
`A record related to an International Application filed underthe Patent Cooperation Treaty in this system of
`records may be disclosed, as a routine use, to the International Bureau ofthe World Intellectual Property
`Organization, pursuant to the Patent Cooperation Treaty.
`A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes
`of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C.
`218(c)).
`A record from this system of records may be disclosed, as a routine use, to the Administrator, General
`Services, or his/her designee, during an inspection of records conducted by GSA as part ofthat agency’s
`responsibility to recommend improvements in records management practices and programs, under authority of
`44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing
`inspection of records forthis purpose, and any other relevant (i.e., GSA or Commerce) directive. Such
`disclosure shall not be used to make determinations about individuals.
`A record from this system of records may be disclosed, as a routine use, to the public afler either publication of
`the application pursuant to 35 U.S.C. 122(b) or issuance ofa patent pursuant to 35 U.S.C. 151. Further, a
`record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public ifthe record
`was filed in an application which became abandoned or in which the proceedings were terminated and which
`application is referenced by either a published application, an application open to public inspection or an issued
`patent.
`A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law
`enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.
`
`2
`
`

`

`‘
`
`
`
`‘
`‘
`
`;
`l
`‘
`
`~
`
`
`
`PTO/Awm (Gs-12)
`Approved for use through 01/31/7014, OMB 0551-0032
`US Patent and Trademark Office; US. DEPARTMENT QF CCEMMERCE
`Under the Papeiwork Reclusfiun Act of 19953, no {remains are required to respond to a collection of information unless it displays a valid OMB control number.
`
`DECLARATEQN (3? CFR 1.63) FOR UTILBTY (3R DESEGN APPLICATEQN USENG AN
`APPLECATEQN DATA SHEET (3? CFR 115}
`
`Ting 0r
`mention
`
`OSTEOCLAST lNHlBlTCRS FQR KNEE CQNDlTlONS
`
`Asihe below named inventor, i hereby declaretliat:
`
`This declaration
`is; directed to:
`
`~
`
`"w
`[:33
`
`-
`.
`w-
`the attached application, or
`
`D United States; application or PCT international application number
`filed on __
`
`The above—identified application was made or authorized to be made by me,
`
`l believe that l am the orig! ai inventor or an original joint inventor oi a claimed invention in the application
`
`1 hereby acknowledge that any willful false statement made in this declaration is punishable under 13 U,.S.Q 1001
`by fine or imprisonment of not more than five (5) years, or both.
`
`WARNENG:
`
`:
`
`‘ T
`
`Petitioner/applicant is; cautioned to avoid submitting personai information in documents. filed in a patent application that may
`mnl‘ribute to identity theft. Personal information such as social security numbers, bank account numbers, or imrlii card numbers.
`(other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO
`to support a petition or an application.
`if this type oi personal information is included in documents submitted to the USPTO,
`;
`petitioners/applicants should consider redacting such personal information from the documents before submitting them to the
`USPTO. Petitioner/applicant is advised that the record of a patent application is available to the publls after publication Gillie
`application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application] or issuance of a
`
`, patent. Furthermore, the record from an abandonedapplicationmay also be available to the public it the iappiwation is
`referenced in a published application or an issued patent (see 37 CFR 114). Checks and credit card authorization forms
`TO—2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.
`
`I
`
`I
`
`LEGAL NAME OF iNVENTOR
`
`invenmrt Hernot Tabuteau
`
`Signature:lHemC"I Tabuieau/
`
`Date (Optima?) :
`
`lute: An applimticn data sheet (P’E'OiSBlM or equivalent), including naming the entire inventive entity, must accompany this form or must have
`in previously tiled. Use an additional P’l‘Q/‘AlA/fiil form for each additional inventor.
`
`his collection of information is required by 35 U.SC.115 and 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and
`by the USPTO to process) an application, Confident
`"
`is governed by 35 U,S,C. 122 and 3.7 CFR 1.1.1. and 1.14 This collection is estimated to take 1 minute to
`
`complete including gathering, preparing, and submitting the completed application form to the USPTCi. Time will vary depending upon the individual case. Any
`
`
`comments on the amount of time you requrre to complete this. term and/or sugge.
`for reducing this burden, should be . t. .l to the Chief information Officer, US
`Patent and Trademark Orrin-e. US, Department at Commeme, PD, Box 1450, Alexandria, VA22313«14SU. DO NOT SEND FEES DR COMPLETED FD RMS TO
`THES ADDRESS. SEND TO: Commissioner for Patents, PI). Box 1450, Alexandria, VA 22313-1456.
`Ifyou need assistance in completing the form, cal! 7-fl001PTO-9199 and select option 2
`
`3
`
`

`

`PTOIAIAI14 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`US. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`-
`
`-
`
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the
`bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.78.
`This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the
`document may be printed and included in a paper filed application.
`
`Secrecy Order 37 CFR 5.2:
`
`El Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to
`37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)
`
`Inventor Information:
`
`
`
`Middle Name
`
`
`Family Name
`
`Non US Residency
`
`Active US Military Service
`
`
`
`Mailing Address of Inventor:
`
`
`
`Address 1
`AddressZ
`
`I5 Broadway, 9th Floor
`
`I_
`
`generated within this form by selecting the Add button.
`
`v
`| statervrovince
`
`Countryi
`Postal Code
`
`All
`
`Inventors Must Be Listed — Additional
`
`Inventor Information blocks may be
`
`
`Correspondence Information:
`
`Enter either Customer Number or complete the Correspondence Information section below.
`
`For further information see 37 CFR 1.33(a).
`
`
`
`D An Address is being provided for the correspondence Information of this application.
`Customer Number
`TI°149
`Email Address
`IDocket@mabr.com
`
`Application Information:
`
`Title of the Invention
`
`
`Osteoclast Inhibitors for Knee Conditions
`
`Attorney Docket Number
`
`‘ 3226.10005US41
`
`Small Entity Status Claimed
`
`
`
`
`SubjectMauer —:
`Total Number of Drawing Sheets (if any)
`Suggested Figure for Publication (if any)
`
`EFS Web 2.2.12
`
`4
`
`

`

`PTOIAIAI14 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`Attorney Docket Number
`A3226.10005US41
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Osteoclast Inhibitors for Knee Conditions
`
`Title of Invention
`
`Filing By Reference:
`
`Only complete this section when filing an application by reference under 35 U.S.C. 1 11(c) and 37 CFR1.57(a). Do not complete this section if
`application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be
`
`provided in the appropriate 5ection(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").
`
`For the purposes of a filing date under 37 CFR1.53(b), the description and any drawings of the present application are replaced by this
`reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).
`i
`
`Application number of the previously
`filed application
`
`Filing date (YYYY—MM-DD)
`
`Intellectual Property Authority or Country
`
`
`
`fififi
`
`
`Publication Information:
`
`D Request Early Publication (Fee required at time of Request 37 CFR 1.219)
`
`Request Not to Publish. I hereby request that the attached application not be published under
`35 U.S.C. 122(b) and certify that the invention disclosed in the attached application has not and will not be the
`subject of an application filed in another country, or under a multilateral international agreement, that requires
`
`publication at eighteen months after filing.
`
`Representative Information:
`
`Representative information should be provided for all practitioners having a power of attorney in the application. Providing
`this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32).
`Either enter Customer Number or complete the Representative Name section below.
`If both sections are completed the customer
`Number will be used for the Representative Information during processing.
`
`US Patent Practitioner 0 Limited Recognition (37 CFR 11.9) Customer Number
`
`0 Customer Number
`I-7149
`
`Please Select One:
`
`
`Domestic BenefithationaI Stage Information:
`This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate
`National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes
`the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
`When referring to the current application, please leave the "Application Number” field blank.
`
`Remove
`
`
`
`
`
`
`Filing or 371(c) Date
`
`
` Prior Application Number
`
`(YYYY-MM-DD)
`
`'016—11—23
`I 15/360886
`
`
`
`
`
`
`
`
`
`Application Number
`
`Continuity Type
`
`l—l ontinuation in part of
`
`EFS Web 2.2.12
`
`5
`
`

`

`PTO/AlA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`Attorney Docket Number
`A3226.10005US41
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`
`
`Prior Application Status_l
`Remove
`
`'
`'
`'
`Issue Date
`"
`
`Application
`Continuity Type
`Prior Application
`Filing Date
`
`
`
`Number
`Number
`(—YYYYMM——DD)
`Patent Number
`(YYYY-MM—DD)
`
`
`I ontinuationIn part ofl I15/217773
`I15/360886
`[016-07—22
`'623038
`017—04—18
`
`Remove
`
`
`
`Prior Application Status_I
`
`
`Prior Application
`Filing Date
`Issue Date
`Application
`.
`.
`
`
`
`
`
`(YYYY-MM-DD)
`Patent Number
`(YYYY-MM-DD)
`Number
`Continuity Type
`Number
`
`l2015—12—11 9408861 l2016—08—09
`
`I 14/967224
`15/217773
`
`ontinuation of
`
`
`
`
`Remove
`
`Prior Application Status I—l
`
`
`
`
`Prior Application
`Filing Date
`Issue Date
`.
`.
`Application
`
`
`
`(YYYY-MM-DD)
`Pater“ Number
`(YYYY—MM—DD)
`Number
`commu'w Type
`Number
`
`
`14/957224
`ontinuation of
`I 14/604524
`r 015—01—23
`v
`I' 015—1 2-15
`
`
`
`Prior Application Status_I
`Remove
`
`
`
`Filing or 371(c) Date
`
`
`
`Prior Application Number
`
`(YYYY-MM-DD)
`
`
`014—11-07
`
`
`
`
`
`
`
`Application Number
`
`Continuity Type
`
`I 4/604524
`
`I ontinuation in part of
`
`I 14/536526
`
`Application
`
`.
`
`.
`
`Prior Application
`
`Filing Date
`
`Issue Date
`
`I14/446184
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`015-04-14
`006279
`I7014—07—29
`I ontinuation in part of "14/446184
`I141535526
`
`
`
`Remove
`Prior Application Status_I
`
`
`
`Application
`.
`.
`Prior Application
`Filing Date
`Issue Date
`(YYYY—MM—DD)
`Patent Number
`(YYYY—MM—DD)
`Number
`Continuity Type
`
`
`014—05—28
`014—09—16
`I—I14l288716
`
`
`
`
`
`
`
`
`Prior Application Number
`
`
`
`
`
`
`
`I014—01—30
`I 61/933608
`I laims beneft of prOVISIonal
`I 4/288716
`
`Prior Application Status_I
`_emove
`Filing Date
`P t
`tN b-lssue Date
`
`Prior Application
`Application
`.
`.
`
`
`
`Number
`
`
`(YYYY—MM—DD)
`39”
`”m 9'
`(YYYY—MM—DD)
`
`
`
`' 014—05—15
`I' 015—05—19
`
`I ontinuation in part of I'M/279229
`
`
`
`Remove
`
`
`
`Prior Application
`Application
`
` Filing Date Issue Date
`
`Continuity Type
`
`
`Number
`Number
`(YYYY-MM-DD)
`Pater“ Number
`(YYYY-MM-DD)
`
`14/279229
`I 14/063979
`' 0113—10—25
`I' 014—08-1 2
`
`
`
`
`
`Application Number
`
`Continuity Type
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`I14536526
`
`ontinuation of
`
`
`
`Application Number
`
`Continuity Type
`
`I__II
`EFS Web 2.2.12
`
`
`Filing or 371(c) Date
`
`(YYYY-MM-DD)
`
`
`
`
`Prior Application Number
`
`
`
`6
`
`

`

`PTOIAIA114 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`Attorney Docket Number A3226.10005US41
`
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`Application Number
`
`Continuity Type
`
`I 31894274
`
`I laims benefit of provisional
`
`I 611803721
`
`Remove
`
`
`
`
`Filing or 371(c) Date
`
`
`
`Prior Application Number
`
`(YYYY-MM-DD)
`
`
`0'13-03—20
`
`
`Filing or 371(c) Date
`(yvyy-M|\/|-DD)
`
`Prior Application Number
`
`Application Number
`
`Continuity Type
`
`Application Number
`
`Continuity Type
`
`
`
`
`
`
`
`
`
`
`
`I 611767647
`I laims benefit of provisional
`I 31894274
`'013—02—21
`
`
`
`
`Prior Application Status Im:
`Remove
`
`
`
`Filing or 371(c) Date
`
`
`
`
` Prior Application Number
`(YYYY-MM-DD)
`
`I013—0221
`I 611767676
`I laims beneft of prOVISIonal
`I 31894274
`
`
`_emove
`Prior Application Status Im:
`Fil-in_gor 371(c) Date
`
`
`
`Prior Application Number
`(YYYY-MM-DD)
`
`
`' 0113—02—14
`I 611764563
`
`
`Remove
`
`
`
`
`Filing or 371(c) Date
`
`
`
` Prior Application Number
`(YYYY-MM-DD)
`
`
`
`'013—02—07
`
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Application Number
`
`Continuity Type
`
`I 31894274
`
`I laims benefitof provisional
`
`Application Number
`
`Continuity Type
`
`I 31894274
`
`I laims benefit of provisional
`
`Application Number
`
`Continuity Type
`
`I 31894274
`
`I laims benefit of provisional
`
`Application Number
`
`Continuity Type
`
`I 31894274
`
`I laims benefit of provisional
`
`Application Number
`
`Continuity Type
`
`I 611762225
`
`Prior Application Number
`
`
`
`
`
`I 611655541
`'012—06—05
`
`
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`
`I 611655527
`'012—06-05
`
`
`
`
`
`
`
`
`
`
` Prior Application Number
`
`
`
`Prior Application Number
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`
`
`I012—06_—01
`I 611654383
`I laimsbeneftofprovisional
`'—31894274
`Fil-in-gor 371(c) Date
`
`
`(YYYY-MM-DD)
`
`'012—06—01
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`I 31894274
`
`EFS Web 2.2.12
`
`I laims benefit of provisional
`
`I 611654292
`
`7
`
`

`

`PTO/AlA/14 (11-15)
`Approved for use through 04/30/2017. OMB 0651-0032
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`Attorney Docket Number A3226.10005US41
`
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`Remove
`
`
`
`
`Filing or 371(c) Date
`
`
`
`Prior Application Number
`
`(YYYY-MM-DD)
`
`
`0'12—05—15
`
`
`Filing or 371(c) Date
`(yvyy-M|\/|-DD)
`
`Prior Application Number
`
`I 61/647478
`
`Application Number
`
`Continuity Type
`
`I 3/894274
`
`I laims benefit of provisional
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Application Number
`
`Continuity Type
`
`Application Number
`
`Continuity Type
`
`Application Number
`
`Continuity Type
`
`Application Number
`
`Continuity Type
`
`
`
`
`
`I 61/646538
`I laims benefit of provisional
`I 3/894274
`'012—05—14
`
`
`
`
`Prior Application Status Im:
`Remove
`
`
`
`Filing or 371(c) Date
`
`
`
`
` Prior Application Number
`(YYYY-MM-DD)
`
`I015—0527
`I PCT/US2015/032739
`I ontinuationIn part of
`I 5/360886
`
`
`_emove
`Prior Application Status Im:
`Fil-in_gor 371(c) Date
`
`
`
`Prior Application Number
`(YYYY-MM-DD)
`
`
`' ()1 4—08—08
`I - CT/USZO15/032739 _l PCT/US2014/050427
`
`
`Remove
`
`
`
`
`Filing or 371(c) Date
`
`
`
` Prior Application Number
`(YYYY-MM-DD)
`
`
`
`014—05—15
`
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`
`
`
`
`
`
`
`
`
`I 15/647140
`017—07—11
`
`
`
`Filing or 371(c) Date
`(YYYY-MM-DD)
`
`
`I 62/378140
`I laims benefitof provisional
`I 5/647140
`'016—08—22
`Additional Domestic Benefit/National Stage Data may be generated within this form
`
`by selecting the Add button.
`
`I - CT/US2014/050427 _I 14/279241
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`I—I ontinuation in part of
`
`Application Number
`
`Continuity Type
`
`Prior Application Number
`
`
`
`Foreign Priority Information:
`
`EFS Web 2.2.12
`
`8
`
`

`

`PTOIAIAI14 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`_
`_
`Application Data Sheet 37 CFR 1.76
`
`A3226.10005US41
`Attorney Docket Number
`
`
`Application Number
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`Add button.
`
`This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet
`
`constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.5_5. When priority is claimed to a foreign application
`that is eligible for retrieval under the priority document exchange program (PDX)l the information will be used by the Office to
`automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate
`responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual
`property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1)_
`
`Remove
`
`Application Number
`
`I
`
`Access Codei (if applicable)
`
`
`
`Additional Foreign Priority Data may be generated within this form by selecting the
`
`
`
`Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition
`
`Applications
`
`
`This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also
`contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March
`D 16, 2013.
`NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March
`16, 2013, will be examined under the first inventor to file provisions of the AIA.
`
`EFS Web 2.2.12
`
`9
`
`

`

`PTOIAIAI14 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`
`Attorney Docket Number A3226.10005US41
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`Osteoclast Inhibitors for Knee Conditions
`
`Title of Invention
`
`Authorization or Opt-Out of Authorization to Permit Access:
`
`When this Application Data Sheet is properly signed and filed with the application, applicant has provided written
`authority to permit a participating foreign intellectual property (IP) office access to the instant application—as-filed (see
`paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant
`application (see paragraph B in subsection 1 below).
`
`Should applicant choose not to provide an authorization identified in subsection 1 below, applicant must opt-out of the
`authorization by checking the corresponding box A or B or both in subsection 2 below.
`
`NOTE: This section of the Application Data Sheet is ONLY reviewed and processed with the INITIAL filing of an
`application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind
`authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.
`
`
`
`1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)
`
`
`A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the
`undersigned hereby grants the USPTO authority to provide the European Patent Office (EPO), the Japan Patent Office
`(JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People’s Republic of
`China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office
`participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign
`application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed
`and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the
`instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)
`(1)-
`
`
`B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt—out of authorization) is checked,
`the undersigned hereby grants the USPTO authority to provide the EPO access to the bibliographic data and search
`results from the instant patent application when a European patent application claiming priority to the instant patent
`application is filed. See 37 CFR 1.14(h)(2).
`
`The applicant is reminded that the EPO’s Rule 141(1) EPC (European Patent Convention) requires applicants to submit a
`copy of search results from the instant application without delay in a European patent application that claims priority to
`the instant application.
`
`2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)
`
`A. Applicant DOES NOT authorize the USPTO to permit a participating foreign IP office access to the instant
`D application-as—filed.
`If this box is checked, the USPTO will not be providing a participating foreign IP office with
`any documents and information identified in subsection 1A above.
`
`|:|
`
`B. Applicant DOES NOT authorize the USPTO to transmit to the EPO any search results from the instant patent
`application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant
`application.
`NOTE: Once the application has published or is othenNise publicly available, the USPTO may provide access to the
`application in accordance with 37 CFR 1.14.
`
`EFS Web 2.2.12
`
`10
`
`10
`
`

`

`PTOIAIAI14 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`
`Attorney Docket Number
`A3226.10005US41
`
`Osteoclast Inhibitors for Knee Conditions
`
`Title of Invention
`
`Applicant Information:
`
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR
`to have an assignment recorded by the Office.
`
`
`1
`Applicant
`If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed.
`The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR
`1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person
`who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an
`applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient
`proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be
`identified in this section.
`
`Legal Representative under 35 U.S.C. 117
`
`Joint Inventor
`
`Person to whom the inventor is obligated to assign.
`
`Person who shows sufficient proprietary interest
`
`If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:
`
`
`
`
`
`
`Name of the Deceased or Legally Incapacitated Inventor:
`
`If the Applicant is an Organization check here.
`
`IX
`
`Mailing Address Information For Applicant:
`
`Address 1-30 FIFTH AVENUE, SUITE 2000
`
`AddressZ
`
`
`
`Email Address
`
`Additional Applicant Data may be generated within this form by selecting the Add button.
`
`Assignee Information including Non-Applicant Assignee Information:
`
`
`Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title
`37 of CFR to have an assignment recorded by the Office.
`
`
`EFS Web 2.2.12
`
`11
`
`11
`
`

`

`PTOIAIAI14 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`US. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Attorney Docket Number A3226.10005US41
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`
`
`Title of Invention
`
`Osteoclast Inhibitors for Knee Conditions
`
`
`
`Assignee 1
`Complete this section if assignee information, including non—applicant assignee information, is desired to be included on the patent
`application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application
`publication as an applicant. For an assignee—applicant, complete this section only if identification as an assignee is also desired on the
`patent application publication.
`Remove
`
`
`
`
`If the Assignee or Non-Applicant Assignee is an Organization check here.
`|:|
`
`Given Name
`
`Middle Name
`
`Family Name
`
`
`
`selecting the Add button.
`
`
`Mailing Address Information For Assignee including Non-Applicant Assignee:
`
`
`
`Phone Number
`
`Fax Number
`
`Email Address
`
`Additional Assignee or Non-Applicant Assignee Data may be generated within this form by
`
`
`
`
`Signature:
`NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). However, if this Application
`Data Sheet is submitted with the INITIAL filing of the application fl either box A or B is n_ot checked in
`subsection 2 of the “Authorization or Opt-Out of Authorization to Permit Access” section, then this form must
`also be signed in accordance with 37 CFR 1.14(c).
`This Application Data Sheet must be signed by a patent practitioner if one or more of the applicants is a juristic
`entity (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a
`
`patent practitioner, all joint inventors who are the applicant, or one or more joint inventor-applicants who have been given
`power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of ill joint inventor-applicants.
`See 37 CFR 1.4(d) for the manner of making signatures and certifications.
`
`01—709— 13
`Date (YYYY-MM- DD)
`uefen Zhoul
`Signature
`
`
` Additional Signature may be generated within this form by selecting the Add button.
`
`First Name
`
`Last Name
`
`Registration Number
`
`3398
`
`EFS Web 2.2.12
`
`12
`
`12
`
`

`

`PTOIAIAI14 (11-15)
`Approved for use through 0413012017. OMB 0651-0032
`U.S. Patent and Trademark Office; US. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
`
`Application Data Sheet 37 CFR 1.76
`Application Number
`
`
`Attorney Docket Number
`A3226.10005US41
`
`Osteoclast Inhibitors for Knee Conditions
`
`Title of Invention
`
`This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which
`is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This
`collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data
`sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, US. Patent and
`Trademark Office, US. Department of Commerce, PO. Box 1450, Alexandria, VA 22313—1450. DO NOT SEND FEES OR
`COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`EFS Web 2.2.12
`
`13
`
`13
`
`

`

`Privacy Act Statement
`
`The Privacy Act of 1974 (PL 93—579) requires that you be given certain information in connection with your submission of the attached form related to a patent
`application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information
`is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary: and (3) the principal purpose for which the information is used by the U.S. Patent and
`Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S.
`Patent and Trademark Office may not be able to process and/or examine your submission, which